SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immucor

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Cash who wrote (281)2/20/1999 12:26:00 PM
From: Thomas Kirwin  Read Replies (1) of 422
 
Corp Com & IBD Musings

Jim,

I believe that Immucor made a wise selection with respects to Corporate Communications. It is my understanding that the price tag placed on their services is calculated at a flat rate. Some other PR/IR firms charge based on outstanding shares. (Example - $0.01 or greater per share) Corporate Communications wont break the bank or highly impact Immucor's earnings.

I saw SERO highlighted in an Investor's Business Daily segment some time ago. Sure hope to see Immucor profiled in a similar fashion sometime soon.

I like the company Corp Com keeps!

Regards,

Tom
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext